DBV TECHNOLOGIE/S (DBVT) Downgraded by Zacks Investment Research
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
Other equities analysts also recently issued research reports about the company. Leerink Swann reissued an outperform rating on shares of DBV TECHNOLOGIE/S in a research report on Thursday, December 20th. BidaskClub raised DBV TECHNOLOGIE/S from a sell rating to a hold rating in a research report on Friday, April 5th. HC Wainwright dropped their price target on DBV TECHNOLOGIE/S from $50.00 to $25.00 and set a buy rating for the company in a research report on Thursday, December 20th. Barclays downgraded DBV TECHNOLOGIE/S from an overweight rating to an equal weight rating and dropped their price target for the stock from $30.00 to $8.00 in a research report on Thursday, December 20th. Finally, ValuEngine downgraded DBV TECHNOLOGIE/S from a buy rating to a hold rating in a research report on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $14.78.
Several large investors have recently made changes to their positions in DBVT. Bank of New York Mellon Corp purchased a new stake in shares of DBV TECHNOLOGIE/S in the third quarter valued at $8,512,000. BlackRock Inc. grew its position in shares of DBV TECHNOLOGIE/S by 0.9% in the third quarter. BlackRock Inc. now owns 312,261 shares of the company’s stock valued at $7,014,000 after purchasing an additional 2,741 shares during the period. FMR LLC grew its position in shares of DBV TECHNOLOGIE/S by 1.4% in the third quarter. FMR LLC now owns 1,325,676 shares of the company’s stock valued at $29,775,000 after purchasing an additional 18,744 shares during the period. Exane Asset Management grew its position in shares of DBV TECHNOLOGIE/S by 30.0% in the third quarter. Exane Asset Management now owns 65,000 shares of the company’s stock valued at $1,460,000 after purchasing an additional 15,000 shares during the period. Finally, First Midwest Bank Trust Division grew its position in shares of DBV TECHNOLOGIE/S by 505.4% in the fourth quarter. First Midwest Bank Trust Division now owns 988,891 shares of the company’s stock valued at $6,349,000 after purchasing an additional 825,533 shares during the period. 44.09% of the stock is owned by institutional investors and hedge funds.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Article: Gross Domestic Product (GDP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.